Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies
- 10 June 2003
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (11) , 1852-1853
- https://doi.org/10.1212/01.wnl.0000068336.84399.9e
Abstract
Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.Keywords
This publication has 8 references indexed in Scilit:
- Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholineNeuroscience, 2002
- Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase InhibitionEuropean Neurology, 2002
- Delusions associated with elevated muscarinic binding in dementia with Lewy bodiesAnnals of Neurology, 2000
- Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)Neurology, 1996
- Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human ConsciousnessBrain and Cognition, 1995
- Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementiaAnnals of Neurology, 1994
- Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodiesNeurology, 1993
- CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPENeuropathology and Applied Neurobiology, 1978